Skip to Main Content

Puzzled by those controversial Alzheimer’s disease data from Biogen and Eisai? We asked an expert to break down what they mean for patients, for science, and for the future of what could be a promising treatment for a devastating disease.

Dr. Howard Fillit, chief science officer of the Alzheimer’s Drug Discovery Foundation, joined us to answer STAT Plus subscribers’ questions on BAN2401, the therapy from Biogen and Eisai that just completed Phase 2 testing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Dear Howard, we did show amyloid plaque removed from the brain 10 years ago with the 1st study with bapineuzumab using C-11 PIB. It very effectively removed amyloid from the brain. Maybe it was space technology then, but it’s true

Comments are closed.